A fluorescence-based high-throughput antiviral compound screening assay against respiratory syncytial virus

Methods in Molecular Biology

Volumn 1030, Issue , 2013, Pages 337-344

  Kwanten, Leen ^a   De Clerck, Ben ^a   Roymans, Dirk ^a  

^a JANSSEN RESEARCH FOUNDATION   (Belgium)

Author keywords

Fluorescence; High throughput screening; Respiratory syncytial virus; RSV inhibitors

Indexed keywords

ENHANCED GREEN FLUORESCENT PROTEIN; PALIVIZUMAB; RIBAVIRIN;

AMINO ACID SEQUENCE; ARTICLE; CONTROLLED STUDY; FLUORESCENCE; HELA CELL; HIGH THROUGHPUT SCREENING; IN VITRO STUDY; NONHUMAN; PRIORITY JOURNAL; RESPIRATORY SYNCYTIAL PNEUMOVIRUS; VIRUS GENOME;

ANTIVIRAL AGENTS; CELL CULTURE TECHNIQUES; GENE EXPRESSION; GENES, REPORTER; HELA CELLS; HIGH-THROUGHPUT SCREENING ASSAYS; HUMANS; MICROBIAL SENSITIVITY TESTS; MICROSCOPY, FLUORESCENCE; RECOMBINATION, GENETIC; RESPIRATORY SYNCYTIAL VIRUS, HUMAN;

EID: 84880121875     PISSN: 10643745     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-1-62703-484-5_26     Document Type: Article

References (14)

1. Krusat T, Streckert HJ (1997) Heparindependent attachment of respiratory syncytial virus (RSV) to host cells. Arch Virol 142:1247-1254
2. Lamb RA (1993) Paramyxovirus fusion: a hypothesis for changes. Virology 197:1-11
3. Martin AJ, Gardner PS, McQuillin J (1978) Epidemiology of respiratory viral infection among paediatric inpatients over a six-year period in north-east England. Lancet 2:1035-1038
4. Weber MW, Mulholland EK, Greenwood BM (1998) Respiratory syncytial virus infection in tropical and developing countries. Trop Med Int Health 268-280
5. Nair H, Nokes DJ, Gessner BD et al (2010) Global burden of acute lower respiratory infections due to respiratory syncytial virus inyoung children: a systematic review and metaanalysis. Lancet 375:1545-1555
6. Falsey AR, Hennessey PA, Formica MA et al (2005) Respiratory syncytial virus infection in elderly and high-risk adults. New England J Medicine 352:1749-1759
7. Collins PL, Crowe JE Jr (2007) Respiratory syncytial virus and metapneumovirus. In: Knipe DM, Howley PM et al (eds) Fields virology. Lippincott Williams & Wilkins, Philadelphia, PA, pp 1601-1646
8. Hallak LK, Spillmann D, Collins PL, Peeples ME (2000) Glycosaminoglycan sulfation requirements for respiratory syncytial virus infection. J Virol 74:10508-10513
9. Hallak LK, Collins PL, Knudson W, Peeples ME (2000) Iduronic acid-containing glycosaminoglycans on target cells are required for effi cient respiratory syncytial virus infection. Virology 271:264-275
10. Cianci C, Genovesi EV, Lamb L et al (2004) Oral effi cacy of a respiratory syncytial virus inhibitor in rodent models of infection. Antimicrob Agents Chemother 48:2448-2454
11. Bonfanti JF, Meyer C, Doublet F et al (2008) Selection of a respiratory syncytial virus fusion inhibitor clinical candidate. Discovery of a morpholinopropylaminobenzimidazole derivative (TMC353121). J Medicinal Chem 51:875-896
12. Ventre K, Randolph AG (2007) Ribavirin for respiratory syncytial virus infection of the lower respiratory tract in infants and young children. Cochrane Database Syst Rev 1:CD000181
13. Chapman J, Abbott E, Alber DG et al (2007) RSV604, a novel inhibitor of respiratory syncytial virus replication. Antimicrob Agents Chemother 51:3346-3353
14. Gupta CK, Leszczynski J, Gupta RK, Siber GR (1996) Stabilization of respiratory syncytial virus (RSV) against thermal inactivation and freeze-thaw cycles for development and control of RSV vaccines and immune globulin. Vaccine 14:1417-1420